Skip to content
MARKETS / NYSE / CCM
NYSE · SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE · SMALL CAP

Concord Medical Services Holdings Ltd. CCM

17 fiscal years on record · CNY · FY2025 reported · SEC filings only
CNY 460.5M
▲ 19.9% YoY
CNY -92.8M
CNY -258.1M
In brief

What this company does

Concord Medical Services Holdings Limited provides oncology healthcare services to cancer patients through self-owned cancer hospitals and clinics, and, through its network business, supplies, manages and provides technical support for medical equipment and software solutions to a network of enterprise customers that includes its hospital partners. As of December 31, 2025, the company had four self-owned cancer hospitals and clinics in operation in China, including one comprehensive cancer hospital, two cancer diagnosis and treatment clinics and one imaging diagnosis center. In 2020, the company renewed its collaboration with MD Anderson for another ten years through a consulting agreement between Concord Hospital Management Group Ltd. (Concord HK), its wholly owned subsidiary in Hong Kong, and MD Anderson. As of the same date, it provided equipment leasing and comprehensive support services for eight cooperative centers based in six hospitals, spanning over six cities across five provinces and administrative regions in China. Under lease and management services arrangements, the company purchases the medical equipment used in its cooperative centers, leases that equipment to hospitals, and receives from the hospital a contracted percentage, typically ranging from 50% to 90%, of each center's revenue net of specified operating expenses.

Written from the business description in Concord Medical Services Holdings Ltd's annual report to the U.S. Securities and Exchange Commission, filed 29 April 2026. Every sentence was checked against that document before publication.

Growth
CNY 460.5M
Revenue, FY2025 · full 17-year series below
Revenue CNY M Net income CNY M
FY2025 · Revenue 460.5 · Net income -92.8
250.0M500.0M-200.0M-400.0M200920112013201520172019202120232025
Compound annual growth
−0.8%
+15.6%
−2.9%
+1.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +15.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−82 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -56.8% · Net -82.4%
20%40%-100%-200%200920112013201520172019202120232025
ROE
FY2019 · ROE -195.2%
-50%-100%-150%200920112013201520172019202120232025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow CNY M
FY2025 · FCF -258.1
200.0M400.0M-250.0M-500.0M200920112013201520172019202120232025
Net buybacks CNY M Dividends CNY M
FY2018 · Dividends 0.0 · Net buybacks 0.0
200M400M-40M-80MDividendsNet buybacks2009201020112012201320142015201620172018

Total assetsCNY 6.5B
EquityCNY -2.1B
CashCNY 297.8M
Gross debtCNY 3.0B
Net debtCNY 2.7B
Current ratio0.48×

Equity was negative — liabilities exceeded assets. No ratio is shown.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · CNY
row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue CNY B0.50.40.50.50.50.20.20.20.30.50.60.60.60.50.50.40.3
Operating income CNY B−0.3−0.5−0.5−0.5−0.5−0.3−0.4−0.3−0.2−0.2−0.00.20.20.2−0.20.20.2
EBITDA CNY B−0.2−0.4−0.4−0.4−0.4−0.3−0.4−0.3−0.1−0.10.10.40.30.3−0.10.30.2
Income tax CNY B0.0−0.0−0.0−0.1−0.0−0.0−0.00.00.00.10.10.10.10.10.00.00.0
Net income CNY B−0.1−0.3−0.3−0.5−0.3−0.3−0.3−0.2−0.3−0.3−0.10.10.10.1−0.20.10.0
Free cash flow CNY B−0.3−0.5−0.4−0.4−0.6−0.4−0.4−0.2−0.1−0.2−0.20.40.20.20.10.10.0
EPS, diluted CNY −0.71−2.35−2.27−3.74−6.26−5.11−4.24−2.76−2.19−2.00−0.580.920.640.95−1.510.890.62
Dividend / sh $··········0.000.000.000.000.00··
Payout %·······−0−0−109−0364··−26·35
ROE %······−195.2−34.3−27.1−20.5−4.96.44.16.6−10.45.9·
Shares out B········0.130.130.130.130.130.140.140.14·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 5 failures in 82 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 13 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente5 failures
ActivityServices-Offices & Clinics of Doctors of Medicine
Listed onNYSE
Incorporated inoutside the United States — SEC code E9
Fiscal year endsnot stated in the filings
Data on record since2009

Share this section

Download image